FDA Approves CLONIDINE HYDROCHLORIDE — Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited announced the approval of its Abbreviated New Drug Application (ANDA091368) for oral clonidine hydrochloride by the FDA, potentially strengthening the firm’s supply chain within the generic hypertension market. This clearance enables Alembic to enter the highly competitive segment for this cardiovascular medication, which could drive incremental volume and share gains against legacy product lines.